Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed high grade serous and/or undifferentiated carcinoma of ovary, fallopian tube or peritoneum~* Oestrogen, progesterone and HER2 negative advanced adenocarcinoma of the breast~* Known BRCA positive breast cancer or ovarian cancer, that is not high grade serous or undifferentiated tubo-ovarian carcinoma.~* Performance status of no more than 2.~Exclusion Criteria:~* Any chemotherapy, radiotherapy ( except palliative), endocrine or immunotherapy within 4 weeks prior to entry~* Major surgery with 4 weeks of entering the study and must have recovered from effects of any major surgery .

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Triple negative breast Cancer with unknown BRCA mutation status: AZD2281 400 mg bid (capsules)/ 300 mg bid (tablets) administered orally~AZD2281, PARP inhibitor Olaparib tablets, oral
- 2 (Type: EXPERIMENTAL): Known BRCA mutation positive breast cancer: AZD2281 400 mg bid (capsules)/ 300 mg bid (tablets) to be administered orally~AZD2281, PARP inhibitor Olaparib tablets, oral
- 3 (Type: EXPERIMENTAL): High grade serous/undifferentiated tubo-ovarian carcinoma with unknown BRCA status: AZD2281 400 mg bid (capsules)/ 300 mg bid (tablets) administered orally~AZD2281, PARP inhibitor Olaparib tablets, oral
- 4 (Type: EXPERIMENTAL): Known BRCA mutation positive ovarian cancer: AZD2281 400 mg bid (capsules)/ 300 mg bid (tablets) administered orally~AZD2281, PARP inhibitor Olaparib tablets, oral

Based on this trial design, predict the completion outcome and termination type (if applicable).